Chemed

Chemed Corp. engages in the provision of healthcare and maintenance services. It operates through the VITAS and Roto-Rooter segments. The VITAS segment offers hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers. The Roto-Rooter segment includes plumbing, drain cleaning, water restoration, and other related services to residential and commercial customers. The company was founded in 1970 and is headquartered in Cincinnati, OH.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Chemed exceeds earnings expectations, focuses on strategic growth initiatives

Chemed's strong financial performance in 2022 was supported by targeted hiring and retention efforts.
Both VITAS and Roto-Rooter are focusing on improving staffing and revenue growth.
Chemed's strategic initiatives position the company well for future growth and operational efficiency.
The company's emphasis on culture and strategic approaches enhances valuation in the M&A market.

Chemed reports strong Q1 performance, optimistic about growth trajectory

Chemed's Q1 2023 earnings call highlighted a positive performance trajectory post-pandemic, with a focus on VITAS' growth and operational strategies. The company addressed challenges related to Medicare reimbursement rates and emphasized opportunities for further expansion and staff satisfaction.

Chemed's VITAS shines, Roto-Rooter adapts to consumer challenges

Chemed's Q2 2023 earnings call highlighted VITAS' strong performance and operational improvements post-pandemic.
Roto-Rooter faced challenges in consumer spending but focused on enhancing online presence and conversion rates.
Both segments showcased resilience amidst economic headwinds, with strategic initiatives in place to drive growth and operational efficiency.
Chemed's strategic cost management and revenue generation strategies position the company for sustainable growth and margin protection.

Chemed reports strong Q3 performance, eyes growth amid economic challenges

Chemed's diversified business segments showed resilience and growth potential, with VITAS Healthcare and Roto-Rooter both demonstrating strengths and addressing challenges. The company remains cautiously optimistic about 2024, focusing on operational efficiency and market dynamics for sustained performance.

Chemed's VITAS shines in Q4 with strong growth, Roto-Rooter faces challenges

Chemed's VITAS segment excelled with strong revenue growth and operational improvements, while Roto-Rooter faced challenges in call volume.
Management's confidence in sustained growth and margin improvement presents opportunities for both VITAS and Roto-Rooter in 2024.
Strategies to address challenges and capitalize on opportunities will be crucial for Chemed's divisions to meet their forecasted targets.
Overall, Chemed's performance in Q4 2023 sets a positive tone for the company's outlook and strategic initiatives moving forward.

Chemed excels in hospice segment, Roto-Rooter faces commercial challenges

Chemed's VITAS segment outperformed, while Roto-Rooter faced challenges, prompting strategic actions to enhance commercial performance and drive growth.

Chemed's VITAS shines in Q2 2024, Roto-Rooter faces revenue challenges

Chemed's VITAS segment is driving revenue growth and margin expansion, while Roto-Rooter faces challenges in revenue decline. The company aims to capitalize on growth opportunities in the hospice services sector.

Chemed's VITAS shines amid Roto-Rooter's challenges in Q3 2024

Chemed's earnings call showcased VITAS' resilience and growth prospects, while addressing Roto-Rooter's challenges and strategic adjustments. The company remains optimistic about adjusted net income outlook for the year.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Chemed Corporation (CHE) CEO Kevin McNamara on Q2 2020 Results - Earnings Call Transcript

CSG Systems International

Lockheed Martin

Providence Service

Quanta Services

Consumer sentiment continues to slide as the count of coronavirus cases keeps increasing in the U.S., putting the economic recovery in doubt.

Best Stocks To Buy Today As Tech Rally Boosts Nasdaq Performance

Chemed (CHE) witnesses solid revenue growth across key subsidiaries in Q2 earnings.

Chemed (CHE) Q2 Earnings Beat Estimates, Margins Decline

Chemed (CHE) delivered earnings and revenue surprises of 16.36% and -1.40%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Chemed (CHE) Beats Q2 Earnings Estimates

CINCINNATI--(BUSINESS WIRE)--Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), one of the nation’s largest providers of end-of-life care, and Roto-Rooter, the nation’s largest commercial and residential plumbing and drain cleaning services provider, reported financial results for its second quarter ended June 30, 2020, versus the comparable prior-year period, as follows: Consolidated operating results: Revenue increased 6.0% to $502 million GAAP Dilut

Chemed Reports Second-Quarter 2020 Results

Chemed (NYSE:CHE) unveils its next round of earnings this Wednesday, July 29. Get prepared with Benzinga's ultimate preview for Chemed's Q2 earnings.

Chemed's Earnings: A Preview

General Dynamics

Home Depot

Science Applications International

Advanced Drainage Systems

After a brief recovery in the early hours, all major indices are currently trading in the red. The rising COVID cases and a debated stimulus package could determine how markets behave in the weeks to come.

Top Stocks To Buy Today As Markets Face Pressure From Rising Unemployment

Chemed (CHE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Chemed (CHE) Reports Next Week: Wall Street Expects Earnings Growth

CINCINNATI--(BUSINESS WIRE)--Chemed Corporation (NYSE:CHE) today announced that it will release financial results for the second quarter ended June 30, 2020, on Wednesday, July 29, 2020, following the close of trading on the New York Stock Exchange. Chemed will host a conference call and webcast at 10 a.m., ET, on Thursday, July 30, 2020, to discuss the company's quarterly results and to provide an update on its business. The toll-free dial-in number for the conference call is 844-743-2500 for

Chemed To Report Second-Quarter 2020 Earnings July 29, Related Conference Call To Be Held On July 30

In the latest trading session, Chemed (CHE) closed at $467.36, marking a +1.62% move from the previous day.

Chemed (CHE) Outpaces Stock Market Gains: What You Should Know

Chemed (CHE) closed the most recent trading day at $456.01, moving +1.3% from the previous trading session.

Chemed (CHE) Gains As Market Dips: What You Should Know

Atrion

Omega Flex

Rollins

“The greatest companies in lousy industries share certain characteristics. They are low-cost operators and penny-pinchers in the executive suite.

An Annual Review on the CORA portfolio

Chemed (CHE) closed at $456.38 in the latest trading session, marking a +0.92% move from the prior day.

Chemed (CHE) Gains But Lags Market: What You Should Know

Synopsys

Teekay Tankers

Tesla

West Pharmaceutical Services

Debt financing is a feasible option as long as the companies succeed in generating a higher rate of return compared to the interest rate

Buy These 5 Low Leverage Stocks to Invest Safely

Chemed (CHE) closed at $478.51 in the latest trading session, marking a -0.78% move from the prior day.

Chemed (CHE) Stock Sinks As Market Gains: What You Should Know

Chemed (CHE) reported earnings 30 days ago. What's next for the stock?

Why Is Chemed (CHE) Up 8.3% Since Last Earnings Report?

Amedisys

Brookdale Senior Living

Ensign Group

There are approximately 35 million Americans aged 65 or older currently and this number is expected to double in the next 25 years.

Silver Tsunami to Hit the United States: 4 Stocks in Focus

Is  (CHE) Outperforming Other Medical Stocks This Year?

Is Chemed (CHE) Stock Outpacing Its Medical Peers This Year?

Chemed (CHE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

What Makes Chemed (CHE) a New Buy Stock

AVITA Medical Inc

These modern healthcare stocks could take care of you very well.

2 Stocks  That Offer Explosive Potential Gains

Chemed Corporation (CHE) CEO Kevin McNamara on Q1 2020 Results - Earnings Call Transcript

Chemed's (CHE) first-quarter 2020 results reflect strong segmental performances amid the coronavirus-led economic doldrums.

Chemed's (CHE) Q1 Earnings Beat Estimates, Margins Improve

Is Chemed (CHE) Outperforming Other Medical Stocks This Year?

Chemed (CHE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Chemed (CHE) Might Surprise This Earnings Season

Cigna

CURO Group Hlds

Huron Consulting Group

Limelight Networks

Five growth stocks with a favorable Zacks Rank that are set to beat first-quarter earnings estimates this month.

News for Chemed Stock (CHE)